0.22

13.39% -0.034

After Hours: .23 0.01 +4.55%

Processa Pharmaceuticals Inc (PCSA)

Overview News Price History Financials Discussions Forecast Stock Split

Processa Pharmaceuticals Inc stock is traded at $0.22, with a volume of 1.26M. It is down -13.39% in the last 24 hours and down -50.88% over the past month. Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Previous Close:

$0.254

Open:

$0.244

24h Volume:

1.26M

Relative Volume:

0.66

Market Cap:

$1.36M

Revenue:

Net Income/Loss:

$-11.53M

P/E Ratio:

-0.0456

EPS:

-4.82

Net Cash Flow:

$-11.12M

1W Performance:

-15.38%

1M Performance:

-50.88%

6M Performance:

-83.33%

1Y Performance:

-86.75%

1-Day Range:

$0.15

$0.2599

1-Week Range:

$0.15

$0.41

52-Week Range:

$0.15

$3.10

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Name

Processa Pharmaceuticals Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

443-776-3133

Address

7380 COCA COLA DRIVE, HANOVER

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

PCSA's Discussions on Twitter

Compare PCSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCSA Processa Pharmaceuticals Inc	0.22	1.36M	0	-11.53M	-11.12M	-4.82
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-25-24	Initiated	H.C. Wainwright	Buy

Processa Pharmaceuticals Inc Stock (PCSA) Latest News

Apr 15, 2025

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025 - GlobeNewswire

Apr 15, 2025

FDA Project Optimus: Processa Unveils New Approach for Rare Disease Treatment Success - Stock Titan

Apr 15, 2025

Apr 12, 2025

Data-Based Insights About Processa Pharmaceuticals Inc (PCSA) - stocksregister.com

Apr 12, 2025

Apr 11, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com UK

Apr 02, 2025

Mar 28, 2025

Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday - Defense World

Mar 28, 2025

Mar 25, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa

Mar 25, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com

Mar 25, 2025

Mar 20, 2025

Processa Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 18, 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference - The Manila Times

Mar 18, 2025

Cancer Therapy Innovator Processa Pharmaceuticals Opens Door to Investors at Elite MedInvest Conference - StockTitan

Mar 18, 2025

Mar 13, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.43 By Investing.com - Investing.com Australia

Mar 13, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.43 - Investing.com India

Mar 13, 2025

Mar 11, 2025

Ulcerated Necrobiosis Lipoidica Market to Expand Significantly by 2034, States DelveInsight Reports | Processa Pharmaceuticals - Barchart

Mar 11, 2025

Mar 04, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.46 - Investing.com

Mar 04, 2025

Feb 28, 2025

Processa Pharma Stock Price, Quotes and Forecasts - Benzinga

Feb 28, 2025

Feb 21, 2025

The Insider Secrets to Processa Pharmaceuticals: A Dark Horse in the Race - Elblog.pl

Feb 21, 2025

Hidden Gems: Why Insiders Are Banking on Processa Pharmaceuticals - Bit Perfect Solutions

Feb 21, 2025